<menu id="y8qua"><menu id="y8qua"></menu></menu>
  • <object id="y8qua"></object>
  • <nav id="y8qua"></nav>

    Pipeline

    Gilead’s research and development program identifies and evaluates investigational compounds that show potential to advance the treatment of life-threatening diseases in areas of unmet medical need.

    Pipeline

    HIV / AIDS

    Gilead is committed to pursuing innovation in HIV across the spectrum of care. We are working to address remaining needs in both prevention and treatment. And, we are focused on discovery research that could potentially, one day, lead to a cure.

    The safety and efficacy of the following investigational compounds or investigational uses of marketed products have not been established. These uses have not been approved by the U.S. Food and Drug Administration or other regulatory authorities.

    • Emtricitabine and tenofovir alafenamide

      Potential Indication: PrEP

      Phase 1
      Phase 2
      Phase 3
    • GS-6207 (Capsid Inhibitor)

      Potential Indication: HIV/AIDS

      Phase 1
      Phase 2
      Phase 3
    • Vesatolimod (TLR-7 agonist)

      Potential Indication: HIV/AIDS

      Phase 1
      Phase 2
      Phase 3
    • Elipovimab (bNab)

      Potential Indication: HIV/AIDS

      Phase 1
      Phase 2
      Phase 3

    Liver Diseases

    Gilead’s liver disease research focuses on investigating medicines for patients with advanced fibrosis due to nonalcoholic steatohepatitis (NASH) and for potentially curing patients chronically infected with the hepatitis B virus (HBV).

    The safety and efficacy of the following investigational compounds or investigational uses of marketed products have not been established. These uses have not been approved by the U.S. Food and Drug Administration or other regulatory authorities.

    • Cilofexor (FXR agonist)

      Potential Indication: NASH

      Phase 1
      Phase 2
      Phase 3
    • Cilofexor (FXR agonist)

      Potential Indication: Primary Biliary Cirrhosis

      Phase 1
      Phase 2
      Phase 3
    • Cilofexor (FXR agonist)

      Potential Indication: Primary Sclerosing Cholangitis

      Phase 1
      Phase 2
      Phase 3
    • Firsocostat (ACC Inhibitor)

      Potential Indication: NASH

      Phase 1
      Phase 2
      Phase 3
    • Selgantolimod (TLR-8 agonist)

      Potential Indication: HBV

      Phase 1
      Phase 2
      Phase 3
    • GS-4224 (PD-L1 Inhibitor)

      Potential Indication: HBV

      Phase 1
      Phase 2
      Phase 3

    Hematology / Oncology

    Gilead is advancing a pipeline of cancer therapies in the areas of cell therapy, immuno-oncology and targeted therapies. Following the 2017 acquisition of Kite Pharma, Inc., our leading cell therapy pipeline now includes investigational cell therapies and next-generation technologies for a range of hematologic malignancies and solid tumors.

    The safety and efficacy of the following investigational compounds or investigational uses of marketed products have not been established. These uses have not been approved by the U.S. Food and Drug Administration or other regulatory authorities.

    • Axicabtagene ciloleucel

      Trial: ZUMA-5 Potential Indication: Indolent NHL

      Phase 1
      Phase 2
      Phase 3
    • Axicabtagene ciloleucel

      Trial: ZUMA-6 Potential Indication: DLBCL (+PD-L1 mAb)

      Phase 1
      Phase 2
      Phase 3
    • Axicabtagene ciloleucel

      Trial: ZUMA-7 Potential Indication: 2nd line DLBCL

      Phase 1
      Phase 2
      Phase 3
    • Axicabtagene ciloleucel

      Trial: ZUMA-11, Potential Indication: DLBCL (+4-1BB)

      Phase 1
      Phase 2
      Phase 3
    • Axicabtagene ciloeucel

      Trial: ZUMA-12 Potential Indication: 1st line DLBCL

      Phase 1
      Phase 2
      Phase 3
    • Axicabtagene ciloleucel

      Trial: ZUMA-14 Potential Indication: DLBCL (+rituximab or lenalidomide)

      Phase 1
      Phase 2
      Phase 3
    • KTE-X19

      Trial: ZUMA-2 Potential Indication: MCL

      Phase 1
      Phase 2
      Phase 3
    • KTE-X19

      Trial: ZUMA-3 Potential Indication: Adult ALL

      Phase 1
      Phase 2
      Phase 3
    • KTE-X19

      Trial: ZUMA-4 Potential Indication: Pediatric ALL

      Phase 1
      Phase 2
      Phase 3
    • KTE-X19

      Trial: ZUMA-8 Potential Indication: CLL

      Phase 1
      Phase 2
      Phase 3
    • KITE-718 (MAGE A3/A6)

      Potential Indication: Solid Tumor

      Phase 1
      Phase 2
      Phase 3
    • KITE-439 (HPV E7)

      Potential Indication: Solid Tumor

      Phase 1
      Phase 2
      Phase 3
    • GS-1423 (bi-specific antibody)

      Potential Indication: Solid Tumor

      Phase 1
      Phase 2
      Phase 3
    • GS-4224 (oral PD-L1 inhibitor)

      Potential Indication: Solid Tumor

      Phase 1
      Phase 2
      Phase 3

    Inflammation / Respiratory

    Gilead is advancing a pipeline of novel investigational agents for inflammatory diseases, addressing multiple targets with potential application across a broad range of disorders.

    The safety and efficacy of the following investigational compounds or investigational uses of marketed products have not been established. These uses have not been approved by the U.S. Food and Drug Administration or other regulatory authorities.

    • Filgotinib (JAK1 inhibitor)

      Potential Indication: Rheumatoid Arthritis

      Phase 1
      Phase 2
      Phase 3
    • Filgotinib (JAK1 inhibitor)

      Potential Indication: Crohn's Disease

      Phase 1
      Phase 2
      Phase 3
    • Filgotinib (JAK1 inhibitor)

      Potential Indication: Ulcerative Colitis

      Phase 1
      Phase 2
      Phase 3
    • Filgotinib (JAK-1 inhibitor)

      Potential Indication: Psoriatic Arthritis

      Phase 1
      Phase 2
      Phase 3
    • Filgotinib (JAK1 inhibitor)

      Potential Indication: Inflammatory Diseases

      Phase 1
      Phase 2
      Phase 3
    • Filgotinib (JAK-1 inhibitor)

      Potential Indication: Ankylosing Spondylitis

      Phase 1
      Phase 2
      Phase 3
    • GS-9876 (Syk inhibitor)

      Potential Indication: Sjogren’s Syndrome

      Phase 1
      Phase 2
      Phase 3
    • GS-9876 (Syk inhibitor)

      Potential Indication: Lupus

      Phase 1
      Phase 2
      Phase 3
    • GS-4875 (TPL2 inhibitor)

      Potential Indication: Ulcerative Colitis

      Phase 1
      Phase 2
      Phase 3
    • GLPG-1690

      Potential Indication: Idiopathic Pulmonary Fibrosis

      Phase 1
      Phase 2
      Phase 3
    • GLPG-1690

      Potential Indication: Systemic Sclerosis

      Phase 1
      Phase 2
      Phase 3
    • Selonsertib (ASK-1 inhibitor)

      Potential Indication: DKD

      Phase 1
      Phase 2
      Phase 3

    Other

    Gilead is collaborating with U.S. Department of Defense, Centers for Disease Control and Prevention, and National Institutes of Health as well as multiple academic institutions to discover and develop novel antivirals for highly pathogenic infections and neglected/emerging viral diseases, including Ebola.

    The safety and efficacy of the following investigational compounds or investigational uses of marketed products have not been established. These uses have not been approved by the U.S. Food and Drug Administration or other regulatory authorities.

    • Remdesivir (GS-5734, Nuc inhibitor)

      Potential Indication: Ebola Virus Infection

      Phase 1
      Phase 2
      Phase 3

    Some of the content on this page is not intended for users outside the US.

    青青草com大香蕉狠恨爱